The 5 Stages Clinical Safety Screens Performed Suicidal thoughts / prior attempt as a checkbox Cancer with 5-year remission threshold (specific clinical wording) End-stage kidney + liver disease (with dialysis qualifier) Organ transplant on anti-rejection medication Diabetic retinopathy as a discrete item Hypertension + sleep apnea checkboxes Seizures + glaucoma in the second multi-select All diabetes types (T1D, T2D on / not on insulin) Medullary Thyroid Cancer (MTC) and Multiple Endocrine Neoplasia type 2 (MEN2) family history are the GLP-1 class FDA black-box warning, and most compounded providers in our catalog ask about them as a dedicated checkbox or a multi-select item
We used the survival and survminer packages in R for generating survival curves and performing statistical tests
Gastrointestinal side effects are by far the most prevalent during early treatment: Nausea Very common (may affect more than 1 in 10 people), typically peaking during the first week and often improving over two to four weeks [1] [2] Vomiting Common (may affect up to 1 in 10 people), usually occurring alongside nausea [1] [2] Diarrhoea Common, may persist for several weeks Constipation Common, sometimes alternating with diarrhoea Abdominal pain or discomfort Common, ranging from mild cramping to more pronounced discomfort Dyspepsia (indigestion) Common Eructation (belching) Common Reduced appetite A therapeutic effect that may feel uncomfortable initially, affecting eating patterns These symptoms arise because semaglutide mimics the natural GLP-1 hormone, which slows gastric emptying and increases satiety
Mounjaro is also licensed for weight management
It ships to the clinic for pickup or directly to your home
For patients ready to explore personalized maintenance dosing strategies, Ivms GLP-1 ID program offers the individualized care, ongoing medical support, and comprehensive tools needed to navigate this phase successfully